Head-to-head · WeighScore
FuturHealth vs yourEra
The verdict
yourEra takes it — 83.8/100 to 65.6/100.
yourEra grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A both-molecule compounded program that publishes its prices up front — semaglutide $199/mo, tirzepatide $299/mo — across a 50-state clinician network, with an optional coaching-plus-labs membership and a NAD+/microdosing menu on the side.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | yourEra |
|---|---|---|
| WeighScore | 65.6/100 | 83.8/100 |
| Grade | C | B |
| Scorecard rank | #215 | #13 |
| Semaglutide | $199/mo (compounded) | $199/mo |
| Tirzepatide | Not disclosed | $299/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #13 · B
Strengths
- Transparent, publicly listed pricing — many compounded competitors hide price behind a quiz
- Both semaglutide and tirzepatide, not a single-drug menu, plus NAD+ and microdosing lines
- Markets a 50-state licensed-clinician network; no insurance required, HSA/FSA accepted
- Optional yourEra Optimum membership adds 1:1 coaching, a nutritionist, at-home lab draws and wearables
Where it loses points
- Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
- Mid-market pricing ($199 sema / $299 tirz) — above the cheapest compounders
- No brand-name lane and no oral route — weekly injectable only
- Thin independent footprint; the 50-state and efficacy claims are self-reported
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.